drugset / Trial / NCT01177306

Inuniv and Working Memory

NCT01177306

Phase 4 Completed 18 enrolled Lori A. Schweickert, MD Shire · collab
NaSingle-groupOpen-labelBasic science

Summary

Minimum 24 subjects aged 8-12 with a diagnosis of ADHD will be prescribed extended release guanfacine (Intuniv) to assess impact, if any, on working memory. Pre and post testing using a standardized battery of tests for effect on symptoms of ADHD and working memory will be administered and assessed.

Timeline

Start
2010-07
Primary completion
2013-12
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Guanfacine Small molecule 1 mg
Subject Guanfacine Small molecule 2 mg
Subject Guanfacine Small molecule 3 mg
Subject Guanfacine Small molecule 4 mg